RATIONALE: Cocaine users have increased regional brain mu-opioid receptor (mOR) binding which correlates with cocaine craving. The relationship of mOR binding to relapse is unknown. OBJECTIVE: To evaluate regional brain mOR binding as a predictor of relapse to cocaine use is the objective of the study. MATERIALS AND METHODS: Fifteen nontreatment-seeking, adult cocaine users were housed on a closed research ward for 12 weeks of monitored abstinence and then followed for up to 1 year after discharge. Regional brain mOR binding was measured after 1 and 12 weeks using positron emission tomography (PET) with [11C]carfentanil (a selective mOR agonist). Time to first cocaine use (lapse) and to first two consecutive days of cocaine use (relapse) after discharge was based on self-report and urine toxicology. RESULTS: A shorter interval before relapse was associated with increased mOR binding in frontal and temporal cortical regions at 1 and 12 weeks of abstinence (Ps < 0.001) and with a lesser decrease in binding between 1 and 12 weeks (Ps < 0.0008). There were significant positive correlations between mOR binding at 12 weeks and percent days of cocaine use during first month after relapse (Ps < 0.002). In multiple linear regression analysis, mOR binding contributed significantly to the prediction of time to relapse (R2= 0.79, P < 0.001), even after accounting for clinical variables. CONCLUSIONS: Increased brain mOR binding in frontal and temporal cortical regions is a significant independent predictor of time to relapse to cocaine use, suggesting an important role for the brain endogenous opioid system in cocaine addiction.
RATIONALE: Cocaine users have increased regional brain mu-opioid receptor (mOR) binding which correlates with cocaine craving. The relationship of mOR binding to relapse is unknown. OBJECTIVE: To evaluate regional brain mOR binding as a predictor of relapse to cocaine use is the objective of the study. MATERIALS AND METHODS: Fifteen nontreatment-seeking, adult cocaine users were housed on a closed research ward for 12 weeks of monitored abstinence and then followed for up to 1 year after discharge. Regional brain mOR binding was measured after 1 and 12 weeks using positron emission tomography (PET) with [11C]carfentanil (a selective mOR agonist). Time to first cocaine use (lapse) and to first two consecutive days of cocaine use (relapse) after discharge was based on self-report and urine toxicology. RESULTS: A shorter interval before relapse was associated with increased mOR binding in frontal and temporal cortical regions at 1 and 12 weeks of abstinence (Ps < 0.001) and with a lesser decrease in binding between 1 and 12 weeks (Ps < 0.0008). There were significant positive correlations between mOR binding at 12 weeks and percent days of cocaine use during first month after relapse (Ps < 0.002). In multiple linear regression analysis, mOR binding contributed significantly to the prediction of time to relapse (R2= 0.79, P < 0.001), even after accounting for clinical variables. CONCLUSIONS: Increased brain mOR binding in frontal and temporal cortical regions is a significant independent predictor of time to relapse to cocaine use, suggesting an important role for the brain endogenous opioid system in cocaine addiction.
Authors: George Bush; Brent A Vogt; Jennifer Holmes; Anders M Dale; Douglas Greve; Michael A Jenike; Bruce R Rosen Journal: Proc Natl Acad Sci U S A Date: 2001-12-26 Impact factor: 11.205
Authors: J Guardia; A M Catafau; F Batlle; J C Martín; L Segura; B Gonzalvo; G Prat; I Carrió; M Casas Journal: Am J Psychiatry Date: 2000-01 Impact factor: 18.112
Authors: Kyle M Kampman; Joseph R Volpicelli; Frank Mulvaney; Margaret Rukstalis; Arthur I Alterman; Helen Pettinati; Robert M Weinrieb; Charles P O'Brien Journal: Addict Behav Date: 2002 Mar-Apr Impact factor: 3.913
Authors: Kathleen T Brady; Susan C Sonne; Robert J Malcolm; Carrie L Randall; Bonnie S Dansky; Kit Simpson; James S Roberts; Michael Brondino Journal: Exp Clin Psychopharmacol Date: 2002-08 Impact factor: 3.157
Authors: Udi E Ghitza; Kenzie L Preston; David H Epstein; Hiroto Kuwabara; Christopher J Endres; Badreddine Bencherif; Susan J Boyd; Marc L Copersino; J James Frost; David A Gorelick Journal: Biol Psychiatry Date: 2010-07-01 Impact factor: 13.382
Authors: Ryan A Selleck; Curtis Lake; Viridiana Estrada; Justin Riederer; Matthew Andrzejewski; Ken Sadeghian; Brian A Baldo Journal: Neuropsychopharmacology Date: 2015-04-13 Impact factor: 7.853